The PPP of dengue vaccines: past, present, and pipeline

Background: recent event Brazil’s Ministry of Health has temporarily suspended the Butantan dengue vaccine (Butantan‑DV) as a precaution after a small number of serious suspected adverse events, including two deaths, were reported in recently vaccinated persons. What happened Brazil halted the pilot dengue vaccination campaign using Butantan‑DV in early June 2026 after reports of two deaths and 42 serious cases with intense abdominal pain, persistent vomiting, and bleeding among recipients. By that point, over 500,000 doses had been given to health‑care workers and people aged 15–49 years in several municipalities. The suspension was framed explicitly as a precautionary measure while causality is assessed, not as a confirmed safety signal. Regulatory and pharmacovigilance response ANVISA, the Ministry of Health, and the Butantan Institute are jointly investigating whether the reported serious events are vaccine‑related, including detailed case review and pharmacovigilance analyses. ANVISA had approved Butantan‑DV in late 2025 for people aged 12–59 years based on...